Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines...
AlphaID™ At Home, the company's first FDA clearance for direct-to-consumer use, enables U.S. adults to screen for their genetic risk of...
Victor Grifols Roura, who devoted 50 years to building Grifols in senior roles including CEO for 30 years, retires as non-executive Chairperson and...
The country, with an increasing immunoglobulin (Ig) usage rate, currently imports about 85% of its Ig demand for patients in Canada who rely on this...
Procleix Plasmodium Assay is a nucleic acid test (NAT) that detects the presence of Plasmodium, a protozoan parasite that causes malaria worldwide...
- Le test Procleix Plasmodium est un test de l'acide nucléique (TAN) qui détecte la présence du Plasmodium, un parasite protozoaire responsable du...
Der Procleix Plasmodium Assay ist ein Nukleinsäuretest (NAT), der das Vorhandensein von Plasmodium nachweist, einem protozoischen Parasiten, der...
- Procleix Plasmodium Assay è un test di acido nucleico (NAT) che rileva la presenza del Plasmodium, un parassita protozoico che causa la malaria in...
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) announced that it has filed its 2021 Annual Report on Form 20-F with the United...
- After obtaining all regulatory approvals, Grifols has closed the acquisition of 100% of the share capital of Tiancheng (Germany) Pharmaceutical...
- La société prévoit de lancer XEMBIFY®, son immunoglobuline sous-cutanée à 20 % pour les immunodéficiences primaires et secondaires, en France, en...
Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a global leader in plasma-derived medicines with more than 110 years of history helping to improve the...
Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines, today announced a collaboration...
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and one of world's top producers of plasma-derived medicines, today...
Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ:GRFS), one of the world's leading producers of plasma-derived medicines with a more than 110-year track record...
- Il sera construit par Grifols Engineering, une référence mondiale dans le développement et la construction d'installations de production avancées...
- To be constructed by Grifols Engineering, a global standard-bearer in the development and building of advanced production facilities for the...
Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of a variety of postexposure...
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100...
Grifols, S.A. ("Grifols") (MCE: GRF), (MCE: GRF.P) and (NASDAQ: GRFS) announced that it has filed its 2020 Annual Report on Form 20-F with the United ...
- Le test Procleix UltrioPlex E renforce la sécurité transfusionnelle en détectant la présence du VIH-1, du VIH-2, du VHB, du VHC et du VHE en un...
- Procleix UltrioPlex E Assay enhances blood safety by detecting the presence of HIV-1, HIV-2, HBV, HCV, and HEV in a single, simultaneous test,...
- Der Procleix UltrioPlex E Assay erhöht die Sicherheit von Blut, indem er das Vorhandensein von HIV-1, HIV-2, HBV, HCV und HEV in einem einzigen,...
-- Il test Procleix UltrioPlex E migliora la sicurezza del sangue rilevando la presenza di HIV-1, HIV-2, HBV, HCV ed HEV con un unico test...
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and leader in the development of...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.